- Home
- XPON vs PHGE Comparison
XPON vs PHGE Comparison
Compare XPON & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XPON | PHGE |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 6.9M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | XPON | PHGE |
|---|---|---|
| Price | $1.11 | $2.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $26.00 |
| AVG Volume (30 Days) | ★ 2.2M | 120.6K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,417,947.00 | N/A |
| Revenue This Year | $61.26 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 109.37 | N/A |
| 52 Week Low | $0.60 | $2.31 |
| 52 Week High | $5.50 | $22.06 |
Technical Indicators
Market Signals| Indicator | XPON | PHGE |
|---|---|---|
| Relative Strength Index (RSI) | 43.74 | 49.68 |
| Support Level | $1.17 | $2.31 |
| Resistance Level | $1.26 | $2.85 |
| Average True Range (ATR) | 0.07 | 0.59 |
| MACD | 0.01 | -0.21 |
| Stochastic Oscillator | 38.64 | 37.08 |
Price Performance
Historical ComparisonAbout XPON Expion360 Inc.
Expion360 Inc is focused on the design, assembly, manufacturing, and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles (RV's) and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).